NSCLCの標的薬ROS1阻害剤市場2020：エンジンの種類別のサイズ、業界分析レポート、地域の見通し、アプリケーションの成長の可能性、価格動向、競争力のある市場シェアと予測、2020年から2025年 (アップデート版あり)

このレポートには、最新の市場図、統計、データが含まれています

ライセンスを選択

概要
目次

まとめグローバルNSCLCの標的薬ROS1阻害剤市場は、世界中で2015年から2019年にかけてCAGR xx％でxxx百万米ドルに達しました。将来的には、2020年から2025年までのCAGR xx％で2020年にxxx百万米ドルに達すると予測されています。
レポートは、主にヨーロッパとアジア太平洋、北アメリカ、中東とアフリカ、南アメリカのグローバルNSCLCの標的薬ROS1阻害剤市場に焦点を当てています。このレポートは、地域、メーカー、アプリケーション、および種類に基づいて市場を分割しました。

さらに、このレポートは、ベンダー間の市場競争状況と会社概要を紹介します。また、市場価格分析とバリューチェーン機能もこのレポートでカバーされています。

メーカー別の市場細分化では、レポートは次の企業をカバーしています-

Roche
Pfizer
Beacon Pharma Limited
Drug International Limted
Incepta Pharmaceuticals

地理的地域による市場細分化では、レポートは次の地域を分析しました-
北米（米国、カナダ、メキシコ）
ヨーロッパ （ドイツ、フランス、イギリス、ロシア、イタリア）
アジア太平洋地域 （中国、日本、韓国、インド、東南アジア）
南アメリカ （ブラジル、アルゼンチン、コロンビアなど）
中東とアフリカ （サウジアラビア、アラブ首長国連邦、エジプト、ナイジェリア、南アフリカ）

タイプによる市場セグメンテーションは以下をカバーします：
クリゾチニブ
Lorlatinib
Entrectinib
他の
アプリケーションによる市場細分化：
NSCLCの扁平上皮癌
NSCLCの腺癌
NSCLCの大細胞癌
ドライバー、拘束、および機会とは別に、レポートはまた、業界で重要な位置を確立するためにプロファイルされたプレーヤーによって採用されたさまざまな成長戦略を含む、競争力のある風景を提供します。包括的なレポートに含まれるセグメンテーションは、立派なメーカーが地域に処理ユニットを設置し、グローバルな存在感を高めるのに役立ちます。これは業界にも利益をもたらし、会社の製品ポートフォリオを増やします。

この調査は、次の重要な質問に対する回答を提供します。
• 2020年から2025年の予測期間におけるNSCLCの標的薬ROS1阻害剤市場の推定成長率と市場シェアおよび規模はどのくらいですか？
• 予測期間2020年から2025年のNSCLCの標的薬ROS1阻害剤市場の原動力は何ですか？
• 著名なマーケットプレーヤーは誰ですか？彼らは他の競合他社に対してどのように競争力を獲得しましたか？
• 世界中のNSCLCの標的薬ROS1阻害剤の業界の進歩に影響を与える市場動向は何ですか？
• 業界の進歩を制限する主な課題と脅威は何ですか？
• 市場は著名な市場プレーヤーにとってどのような機会を持っていますか？
このレポートに関する特別な要件がある場合は、お知らせください。カスタムレポートを提供できます。

注–より正確な市場予測を提供するために、COVID-19の影響を考慮して、すべてのレポートが配信前に更新されます。

Table of Contents

1 Targeted Drug ROS1 Inhibitors for NSCLC Market Overview
1.1 Product Overview and Scope of Targeted Drug ROS1 Inhibitors for NSCLC
1.2 Classification of Targeted Drug ROS1 Inhibitors for NSCLC by Types
1.2.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Comparison by Types (2020-2025)
1.2.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Types in 2018
1.2.3 Crizotinib
1.2.4 Lorlatinib
1.2.5 Entrectinib
1.2.6 Other
1.3 Global Targeted Drug ROS1 Inhibitors for NSCLC Market by Application
1.3.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Market Share Comparison by Applications (2015-2025)
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drug ROS1 Inhibitors for NSCLC Market by Regions
1.4.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size (Million USD) Comparison by Regions (2015-2025)
1.4.1 North America (USA, Canada and Mexico) Targeted Drug ROS1 Inhibitors for NSCLC Status and Prospect (2015-2025)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drug ROS1 Inhibitors for NSCLC Status and Prospect (2015-2025)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drug ROS1 Inhibitors for NSCLC Status and Prospect (2015-2025)
1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drug ROS1 Inhibitors for NSCLC Status and Prospect (2015-2025)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drug ROS1 Inhibitors for NSCLC Status and Prospect (2015-2025)
1.5 Global Market Size of Targeted Drug ROS1 Inhibitors for NSCLC (2015-2025)
2 Manufacturers Profiles
2.1 Roche
2.1.1 Business Overview
2.1.2 Targeted Drug ROS1 Inhibitors for NSCLC Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Roche Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.2 Pfizer
2.2.1 Business Overview
2.2.2 Targeted Drug ROS1 Inhibitors for NSCLC Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.3 Beacon Pharma Limited
2.3.1 Business Overview
2.3.2 Targeted Drug ROS1 Inhibitors for NSCLC Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.4 Drug International Limted
2.4.1 Business Overview
2.4.2 Targeted Drug ROS1 Inhibitors for NSCLC Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.5 Incepta Pharmaceuticals
2.5.1 Business Overview
2.5.2 Targeted Drug ROS1 Inhibitors for NSCLC Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
3 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Competition, by Players
3.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Share by Players (2015-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Targeted Drug ROS1 Inhibitors for NSCLC Players Market Share
3.2.2 Top 10 Targeted Drug ROS1 Inhibitors for NSCLC Players Market Share
3.3 Market Competition Trend
4 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Regions
4.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Market Share by Regions
4.2 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
4.3 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
4.4 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
4.5 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
4.6 Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
5 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries
5.1 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries (2015-2019)
5.2 USA Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
5.3 Canada Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
5.4 Mexico Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries
6.1 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries (2015-2019)
6.2 Germany Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6.3 UK Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6.4 France Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6.5 Russia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6.6 Italy Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries
7.1 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries (2015-2019)
7.2 China Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7.3 Japan Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7.4 Korea Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7.5 India Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7.6 Southeast Asia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
8 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries
8.1 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries (2015-2019)
8.2 Brazil Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
8.3 Argentina Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
8.4 Colombia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9 Middle East and Africa Revenue Targeted Drug ROS1 Inhibitors for NSCLC by Countries
9.1 Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries (2015-2019)
9.2 Saudi Arabia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9.3 UAE Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9.4 Egypt Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9.5 Nigeria Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9.6 South Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
10 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Segment by Type
10.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Market Share by Type (2015-2019)
10.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Forecast by Type (2020-2025)
10.3 Crizotinib Revenue Growth Rate (2015-2025)
10.4 Lorlatinib Revenue Growth Rate (2015-2025)
10.5 Entrectinib Revenue Growth Rate (2015-2025)
10.6 Other Revenue Growth Rate (2015-2025)
11 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Segment by Application
11.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Application (2015-2019)
11.2 Targeted Drug ROS1 Inhibitors for NSCLC Market Forecast by Application (2020-2025)
11.3 Squamous Cell Carcinoma of NSCLC Revenue Growth (2015-2019)
11.4 Adenocarcinoma of NSCLC Revenue Growth (2015-2019)
11.5 Large Cell Carcinoma of NSCLC Revenue Growth (2015-2019)
12 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Forecast (2020-2025)
12.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Forecast (2020-2025)
12.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Forecast by Regions (2020-2025)
12.3 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
12.4 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
12.5 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
12.6 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
12.7 Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source